Lukas Biomedical
Advancing Cancer Treatments

Liver cancer demands the need for better approaches in oncology treatment.

While the traditional surgical procedures like liver resection or transplantation and techniques like radiofrequency ablation are effective to some degree, liver cancer patients and healthcare providers often grapple with the risk of tumor recurrence.

This is where Lukas Biomedical makes its mark.

The pioneering biotechnology company has emerged with a distinctive treatment approach that combines cell therapy with traditional surgical and ablation interventions to address liver cancer comprehensively.

Lukas Biomedical specializes in immune cell therapy technology specifically designed for cancer treatment. Its groundbreaking innovation, LuLym-T cell immunotherapy, leverages the unique capabilities of memory T-cells. These specialized immune cells have been honed within the body to recognize and combat a diverse range of tumor antigens. A significant challenge faced by many cancer patients is the deficiency of these critical memory T cells, which allows tumors to flourish unchecked and transform into malignant entities.

The key is in isolating these rare memory T cells from cancer patients’ blood. Through Lukas Biomedical’s unique process, these cells are expanded, their functionality is enhanced, and their responsiveness is stimulated, empowering them to efficiently recognize and combat cancer. It can magnify the number of these cells to approximately 10 billion per dose, equipping the body’s immune system to mount a more effective defense against cancer.

“Our cell therapy’s minimally invasive nature and reduced side effects presents a promising avenue. It has demonstrated the capacity to reduce the risk of cancer recurrence from 75 percent to approximately 40 percent, drawing upon past clinical studies conducted in Japan,” says Eric Tang, chairman and CEO of Lukas Biomedical.

LuLym-T’s potential is illustrated in a case where a patient with advanced oral cancer underwent combined treatment with cell therapy, chemotherapy, and radiation, and continues to survive. Surprisingly, the patient’s brother, who had the same type of cancer and shared similar backgrounds, tragically passed away within a year. This case serves as a powerful and promising demonstration of the efficacy of cell therapy, showcasing distinct results in two patients with comparable backgrounds but varying treatments.

Lukas Biomedical, based in Taiwan, has successfully launched memory T cell therapy for clinical trials. It is actively working on new treatments, including dendritic cell (DC) memory T cell therapy. This involves extracting a patient’s tumor biopsy, performing DNA sequencing to identify specific tumor antigens, and enhancing the patient’s memory T cells with these antigens. This approach will boost the body’s ability to recognize and eliminate cancer. Currently, the treatment is in the research phase, with plans for clinical trials and commercialization.

Additionally, Lukas is exploring the use of natural killer (NK) cells, which can be derived from healthy donors (allogenic). Unlike autologous cell therapies, NK cells don’t require personal ID matching, enabling easier mass production and administration to patients.

Lukas’s core focus areas encompass autologous cell therapy using a patient’s cells, allogenic cell therapy from healthy donors, ongoing genetic therapy research, and plans for CAR-related therapy, customizing cancer treatments based on a database of unique antigens.

Lukas’s technology, which originated in Japan, where a phase three clinical trial showed a 33 percent reduction in liver cancer recurrence, is offering hope for the prevalent Asian population with hepatitis B and hepatitis C.

In Taiwan, it is providing fee-based therapy for end-stage cancer patients. The holistic approach embodied by Lukas has amassed real-world data and expertise in treating various cancers, including neck, breast, lung, liver, and gastric cancer.

Lukas is a self-sustaining biotech company with over a decade of history. It is financially independent, with a profitable hospital consultation department and an e-commerce division for health products. It is in the pre-IPO stage, planning to go public to expedite U.S. clinical trials from phase two to three, expand into European and Western markets, and form partnerships in Southeast Asia.

The unique strength of Lukas lies in its team of medical doctors who ensure that the company’s medical treatments and technologies are rooted in scientifically backed evidence. Their overarching mission is affording cancer patients improved quality of life and health.